Brief: AIM Immunotech Reports First Quarter Financial Results And Provides Pipeline Update
15/05/2023 13:47
May 15 (Reuters) - AIM ImmunoTech Inc AIM.A :
* AIM IMMUNOTECH REPORTS FIRST QUARTER FINANCIAL RESULTS AND
PROVIDES PIPELINE UPDATE
* AIM IMMUNOTECH INC - PHASE 2 ADVANCED RECURRENT OVARIAN
CANCER
INTERIM RESULTS EXPECTED Q3 2023
* AIM IMMUNOTECH INC - AS OF MARCH 31, 2023, REPORTED CASH,
CASH
EQUIVALENTS AND MARKETABLE SECURITIES OF $30.8 MILLION
* AIM IMMUNOTECH INC - CASH RUNWAY EXPECTED TO FUND
OPERATIONS
THROUGH MULTIPLE KEY MILESTONES THROUGH END OF 2024
* AIM IMMUNOTECH INC - QTRLY NET LOSS PER SHARE FROM
OPERATIONS
$0.08
Source text for Eikon: ID:nGNX2XV3rW
Further company coverage: AIM.A
((Reuters.Brief@thomsonreuters.com;))
Recent news on AIM ImmunoTech
See all newsBrief: Aim Immunotech Duripanc Primary Endpoint Analysis To Begin December 2026 Topline Results Expected Q1 2027
Brief: Aim Immunotech Files To Offer And Resell Up To 13.08 Million Shares Of Common Stock By Selling Stockholders
Brief: AIM ImmunoTech Announces $2.65 Million Financing Priced At-Market Under NYSE American Rules
Brief: Aim Immunotech Announces Significant Increase In Stockholder Equity And Extension Of Promissory Note Maturity Date To June 2027
Brief: Aim Immunotech Announces 50% Objective Response Rate (Orr) In Upmc Recurrent Ovarian Cancer Phase 2 Clinical Trial, Suggesting Breakthrough Combination Potential